Category Archives: Global News Feed

- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -

See the rest here:
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Provides Full Year 2024 Financial Guidance Provides Full Year 2024 Financial Guidance

View post:
Certara Reports Fourth Quarter 2023 Financial Results

- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite -

Read this article:
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metageno­mi, Inc. (Nas­daq: MGX), a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­nomics-derived gene edit­ing tool­box, today announced that Brian C. Thomas, CEO & Founder, will participate in a panel titled, “Emerging Genetic Therapy Approaches,” during the 44th Annual Cowen Healthcare Conference on Wednesday, March 6, 2024 from 12:50-1:50 PM ET in Boston.

See the original post:
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2023 and revenues for 2023.

Visit link:
GENFIT Announces Revenues and Cash Position as of December 31, 2023

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately.

Go here to read the rest:
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET.

Read the original:
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time

Original post:
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Appointment Paves the Way for Company’s Next Chapter in Commercialization Phase of AI-Powered DeepView Device for Predictive Wound Care

Originally posted here:
Spectral AI Appoints Peter M. Carlson as CEO

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference.

Continue reading here:
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference